These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7906175)

  • 41. Improving the oral bioavailability of sulpiride by a gastric-retained form in rabbits.
    Kohri N; Naasani I; Iseki K; Miyazaki K
    J Pharm Pharmacol; 1996 Apr; 48(4):371-4. PubMed ID: 8794985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Tolerance of sultopride (author's transl)].
    Penochet JC
    Sem Hop; 1979 Feb 18-25; 55(7-8):408-9. PubMed ID: 35835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans.
    Bressolle F; Brès J; Fauré-Jeantis A
    J Pharm Sci; 1992 Jan; 81(1):26-32. PubMed ID: 1619566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of sultopride in a case of neuroleptic-induced late dyskinesia].
    Leclere A; Plichart P
    Sem Hop; 1982 Nov; 58(42):2492-3. PubMed ID: 6130603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fatal intoxication with amisulpride and presentation of organ distribution].
    Musshoff F; Kröner L; Padosch SA; Madea B
    Arch Kriminol; 2005; 215(5-6):158-63. PubMed ID: 15991733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Substituted benzamides].
    Scotto JC
    Encephale; 1975; 1(3):223-5. PubMed ID: 6257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
    Sparshatt A; Taylor D; Patel MX; Kapur S
    Acta Psychiatr Scand; 2009 Dec; 120(6):416-28. PubMed ID: 19573049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations.
    Brès J; Bressolle F
    J Pharm Sci; 1991 Dec; 80(12):1119-24. PubMed ID: 1815069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Torsades de pointes during sultopride poisoning].
    Montaz L; Varache N; Harry P; Aymes C; Turcant A; Delille F; Simonin D; Hass C
    J Toxicol Clin Exp; 1992 Dec; 12(8):481-6. PubMed ID: 1364061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of the amisulpride isomers on rat catalepsy.
    Marchese G; Bartholini F; Ruiu S; Casti P; Saba P; Gessa G; Pani L
    Eur J Pharmacol; 2002 May; 444(1-2):69-74. PubMed ID: 12191584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of the amisulpride isomers on rat prolactinemia.
    Marchese G; Ruiu S; Casti P; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jul; 448(2-3):263-6. PubMed ID: 12144950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Liquid Chromatography-Tandem Mass Spectrometry Method for Quantifying Amisulpride in Human Plasma and Breast Milk, Applied to Measuring Drug Transfer to a Fully Breast-Fed Neonate.
    OʼHalloran SJ; Wong A; Joyce DA
    Ther Drug Monit; 2016 Aug; 38(4):493-8. PubMed ID: 27027463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors.
    Castelli MP; Mocci I; Sanna AM; Gessa GL; Pani L
    Eur J Pharmacol; 2001 Dec; 432(2-3):143-7. PubMed ID: 11740949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereoselective pharmacokinetics and metabolism of the enantiomers of cyclophosphamide. Preliminary results in humans and rabbits.
    Holm KA; Kindberg CG; Stobaugh JF; Slavik M; Riley CM
    Biochem Pharmacol; 1990 Apr; 39(8):1375-84. PubMed ID: 2322319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.
    Vernaleken I; Siessmeier T; Buchholz HG; Härtter S; Hiemke C; Stoeter P; Rösch F; Bartenstein P; Gründer G
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):421-30. PubMed ID: 15683553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.
    Rosenzweig P; Canal M; Patat A; Bergougnan L; Zieleniuk I; Bianchetti G
    Hum Psychopharmacol; 2002 Jan; 17(1):1-13. PubMed ID: 12404702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring.
    Gschwend MH; Arnold P; Ring J; Martin W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):132-9. PubMed ID: 16386474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stereoselective blockade of cerebral dopamine receptors by sulpiride and sultopride [proceedings].
    Clow A; Jenner P; Marsden CD; Reavill C; Theodorou A
    Br J Pharmacol; 1979 Nov; 67(3):433P. PubMed ID: 497556
    [No Abstract]   [Full Text] [Related]  

  • 59. Amisulpride-CD-Loaded Liposomes: Optimization and In Vivo Evaluation.
    Shukr MH; Ahmed Farid OA
    AAPS PharmSciTech; 2018 Aug; 19(6):2658-2671. PubMed ID: 29943282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparative trials on sultopride and fluanisone].
    Robert G
    Encephale; 1978; 4(2):145-161. PubMed ID: 28939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.